Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03209063
Other study ID # TROPGP
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 1, 2022
Est. completion date September 30, 2022

Study information

Verified date June 2022
Source Assiut University
Contact Hanan G Abdelazim, prof.doctor
Phone 01227370520
Email hanangalal2000@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss(RPL) usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies.approximately 40% of couples will have an etiology identified that could be associated with their loss.


Description:

Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies.approximately 40% of couples will have an etiology identified that could be associated with their loss.Thrombophilia is the tendency to develop thromboses due to inherited defects in the coagulation system.Thrombophilia was identified as a major cause of RPL,Because pregnancy is a hypercoagulable state, thromboembolism is the leading cause of antepartum and postpartum maternal mortality .The four most common genetic markers for thrombophilia are; prothrombin gene mutation(FII, G20210A), methylene tetra hydrofolate reductase mutations (MTHFR ,C677T and A1298C), factor V Leiden (FVL, G1691A) , and plasminogen activator inhibitor 1 (PAI-1) . Prothrombin G20210A refers to a human gene mutation that increases the risk of blood clots . Approximately 1 in 50 people in the white population in the United States and Europe has prothrombin thrombophilia. Study was conducted to evaluate the frequency of PT20210 among healthy Egyptians, (1.06%) had PT20210 G-A mutation.The variant causes elevated plasma prothrombin levels (hyperprothrombinemia), Prothrombin is the precursor to thrombin, which plays a key role in causing blood to clot (blood coagulation).Prothrombin G20210A can thus contribute to a state of hypercoagulability . Methylene tetra hydrofolate reductase (MTHFR) is the rate-limiting enzyme in the methyl cycle, and it is encoded by the Methylene tetra hydrofolate reductase gene. It was thought that deficient Methylene tetra hydrofolate reductase, by causing elevated homocysteine levels, led to an increased risk of venous thrombosis, coronary heart disease, and recurrent pregnancy loss . Previous studies suggested that percentage of PT20210 in patients with unexplained RPL is ( 10.9%),however searching literatures didn't find any estimation of this percentage in Egyptian population.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 285
Est. completion date September 30, 2022
Est. primary completion date August 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 17 Years to 35 Years
Eligibility Inclusion Criteria 1. Age less than 35 years. 2. History of two or more spontaneous miscarriages Exclusion Criteria: 1. Age more than 35 years. 2. . Women with elevated level of TSH above (2.5 mIU/ml) and uncontrolled DM. 3. Women with autoimmune disorder (antiphospholipid antibody syndrome)with LA1/LA2 ratio more than( 1.2). 4. Women receiving oral contraceptive pills and anticoagulant drugs.

Study Design


Intervention

Diagnostic Test:
polymerase chain reaction
diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Farahmand K, Totonchi M, Hashemi M, Reyhani Sabet F, Kalantari H, Gourabi H, Mohseni Meybodi A. Thrombophilic genes alterations as risk factor for recurrent pregnancy loss. J Matern Fetal Neonatal Med. 2016;29(8):1269-73. doi: 10.3109/14767058.2015.1044431. Epub 2015 Jul 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The study will compare the percentage of prothrombin gene and MTHFR gene polymorphisms in cases with recurrent miscarriage and healthy control group. using polymerase chain reaction Polymerase chain reaction 2 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01419392 - Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages Phase 4
Completed NCT00193674 - Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage Phase 3
Completed NCT06001060 - Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
Recruiting NCT05034250 - Iron Status in Female Infertility and Recurrent Miscarriage
Completed NCT02681627 - Sim (Scratch in Miscarriage) Study N/A
Recruiting NCT02303171 - Use of Warfarin After the First Trimester in Pregnant Women With APS Phase 4
Completed NCT02305420 - EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage Phase 4
Recruiting NCT05824897 - The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
Completed NCT03023137 - Walking and Dietary Modification for Recurrent Early Miscarriages N/A
Not yet recruiting NCT03132779 - Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion Phase 1
Completed NCT02184741 - A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage Phase 3
Active, not recruiting NCT02156063 - A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL) Phase 2
Recruiting NCT03902912 - Effect of Prednisolone Treatment on Uterine Natural Killer Cells Phase 3
Completed NCT03970954 - Low-dose Interleukin-2 in Women With Unexplained Miscarriages Phase 1/Phase 2
Not yet recruiting NCT06249230 - The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk
Recruiting NCT05725512 - Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages Phase 4
Recruiting NCT05267678 - Nutritional Deficiency and Recurrent Miscarriage
Completed NCT02504281 - Study on the Association Between SXCI and RM and the Possible Genetic Mechanism
Completed NCT02694367 - Expression of EPK in Recurrent Miscarriage N/A
Completed NCT01608347 - Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Phase 4